Figure 7From: PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritisPDL241 had no effect on clinical parameters in the rhesus monkey CIA model. The analysis of all animals showed no effect of PDL241 on (A) bodyweight loss relative to day 0; (B) average clinical score; and (C) serum CRP levels. PDL241 treatment had no effect on (D) disease free survival or (E) overall survival. CIA, collagen-induced arthritis; CRP, C-reactive protein.Back to article page